•Participants must have one of the following histologically or cytologically confirmed metastatic or unresectable solid tumor types:

•* Parts A and B

•* Ovarian cancer

•* Endometrial cancer

•* Non-small cell lung cancer (NSCLC)

•* Gastric cancer, including gastroesophageal junction (GEJ) carcinoma

•* Cervical cancer

•* Malignant testicular germ cell tumor (GCT), except for pure teratomas

•* Malignant ovarian GCT, except for pure teratomas

•* Malignant extragonadal GCT except for pure teratomas or tumors with primaries arising from CNS

•* Part C

•* High-grade serous ovarian cancer (HGSOC): Participants must have HGSOC which has progressed or relapsed within 6 months after previous platinum containing chemotherapy, received 2 to 4 prior anticancer lines of therapy, and at least 1 line of therapy in the platinum-resistant setting. If eligible at least 1 line of therapy must have contained bevacizumab or a biosimilar to bevacizumab.

•* Endometrial Cancer: Participants must have unresectable locally advance or metastatic endometrial carcinoma and have had at least 1 prior line of therapy.

•* NSCLC: Participants must have unresectable locally advanced or metastatic NSCLC and have received platinum-based therapy and a PD-(L)1 inhibitor.

•* Gastric cancer or GEJ carcinoma: Participants must have unresectable locally advanced or metastatic gastric cancer or GEJ carcinoma and have received prior platinum and fluoropyrimidine -based chemotherapy

•Participants enrolled in the following study parts should have an appropriate tumor site and agree to a biopsy

•* Part B dose and schedule optimization cohorts and Part C disease-specific expansion cohorts: pretreatment biopsy, unless clinically infeasible following consultation with the medical monitor.

•* Part C biology expansion cohort: pretreatment biopsy (required), on-treatment biopsy during Cycle 1 (unless clinically infeasible following consultation with the medical monitor)

•Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1

•Measurable disease per the RECIST v1.1 at baseline

A Study of SGN-ALPV in Advanced Solid Tumors

What this study is about

Save this trial guide to your notes

Sponsors

Related studies

A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer

A Study of BMS-986504 in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

Trial snapshot

Condition

Locations shown

For caregivers